Five-lipoxygenase-activating protein-mediated CYLD attenuation is a candidate driver in hepatic malignant lesion.

导出 LinkOut

翻译打印收藏纠错

作者： Kun-Kai,Su ^[1] ; Xue-Hua,Zheng ^[2] ; Christian,Bréchot ^[3] ; Xiao-Ping,Zheng ^[4] ; Dan-Hua,Zhu ^[5] ; Rong,Huang ^[6] ; Yan-Hong,Zhang ^[1] ; Jing-Jing,Tao ^[2] ; Yi-Jia,Lou ^[6] ; Lan-Juan,Li ^[1]

作者单位： State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. ^[1] National Clinical Research Center for Infectious Diseases, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. ^[2] Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China. ^[3] Department of Pharmacology, Shengjing Hospital, China Medical University, Shenyang, China. ^[4] Institut Pasteur, Paris, France. ^[5] Department of Pathology, Shulan (Hangzhou) Hospital, Hangzhou, China. ^[6]

关键词 5-lipoxygenase pathway candidate biomarker hepatocellular carcinoma lipid pro-inflammatory mediators median survival time

DOI 10.3389/fonc.2022.912881

PMID 35978827

发布时间 2022-08-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in oncology

2022年12卷

912881页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Five-lipoxygenase-activating protein-mediated CYLD attenuation is a candidate driver in hepatic malignant lesion.

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Five-lipoxygenase-activating protein-mediated CYLD attenuation is a candidate driver in hepatic malignant lesion.

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

检索历史清除